RxDoctor Payments DataLook up a doctor →

Eric Schnakenberg, MD

Family Medicine · Halfmoon, NYNPI 1831128206

Payments from drug & device makers

$189,903in general payments, 2019–2025

Across 795 payments — averaging $238.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$181K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • AstraZeneca$762
  • Pfizer$508
  • plus $4K from 48 others

What the payments were for

  • Speaking & faculty fees$158,82584%
  • Travel & lodging$15,6418%
  • Food & beverage$15,3528%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$189,903 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$122,214
Medicare patients
306
Services billed
2,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol208$221,054
JardianceEmpagliflozin122$175,037
EliquisApixaban107$107,206
OzempicSemaglutide64$98,943
TrulicityDulaglutide60$75,851
Soliqua 100-33Insulin Glargine/Lixisenatide60$60,324
Xultophy 100-3.6Insulin Degludec/Liraglutide21$39,583
InvokanaCanagliflozin17$27,426
Xigduo XrDapaglifloz Propaned/Metformin25$25,289
NuedextaDextromethorphan Hbr/Quinidine12$21,468
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,162
MounjaroTirzepatide11$18,768
MyrbetriqMirabegron23$18,220
ShingrixVaricella-Zoster Ge/As01b/Pf76$15,868
LinzessLinaclotide11$12,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$762$230,638220 claims
Boehringer IngelheimJardiance$1,103$175,037122 claims
Novo NordiskOzempic, Xultophy 100-3.6$1,245$138,52685 claims
PfizerEliquis$508$107,206107 claims
Lilly USA, LLCTrulicity, Mounjaro$288$94,61971 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$306$60,32460 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$180,688$57,837166 claims
Johnson & JohnsonInvokana$181$27,42617 claims
Avanir Pharmaceuticals, Inc.Nuedexta$48$21,46812 claims
Astellas Pharma US IncMyrbetriq$333$18,22023 claims
AbbVieLinzess, Synthroid$1,582$14,56158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Halfmoon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →